Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to -$2.6 million.

  • Oncology Institute's Net Cash Flow fell 12399.34% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.9 million, marking a year-over-year decrease of 20031.71%. This contributed to the annual value of $16.2 million for FY2024, which is 1692.68% down from last year.
  • Oncology Institute's Net Cash Flow amounted to -$2.6 million in Q3 2025, which was down 12399.34% from -$9.4 million recorded in Q2 2025.
  • Oncology Institute's 5-year Net Cash Flow high stood at $103.6 million for Q4 2021, and its period low was -$47.4 million during Q4 2022.
  • For the 5-year period, Oncology Institute's Net Cash Flow averaged around $1.1 million, with its median value being -$1.4 million (2023).
  • Within the past 5 years, the most significant YoY rise in Oncology Institute's Net Cash Flow was 391957.94% (2021), while the steepest drop was 337901.78% (2021).
  • Quarter analysis of 5 years shows Oncology Institute's Net Cash Flow stood at $103.6 million in 2021, then plummeted by 145.75% to -$47.4 million in 2022, then surged by 112.56% to $6.0 million in 2023, then crashed by 65.04% to $2.1 million in 2024, then tumbled by 226.57% to -$2.6 million in 2025.
  • Its Net Cash Flow was -$2.6 million in Q3 2025, compared to -$9.4 million in Q2 2025 and -$9.9 million in Q1 2025.